MIM
EDIT icon

Macroview Investment Management’s Editas Medicine EDIT Stock Holding History

Macroview Investment Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7
Closed -$55 – 688
2023
Q3 		$55 Buy
+7
New +$60 ﹤0.01% 785

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Macroview Investment Management's EDIT Position: Q4 2023 in Review

Macroview Investment Management sold out of Editas Medicine (EDIT) in Q4 2023, closing a stake of 7 shares — an estimated $55 sold.

Macroview Investment Management first reported a position in EDIT in Q3 2023 and held it in 1 quarter. The position peaked at $55 in Q3 2023. 225 funds tracked by Wall St. Rank hold EDIT as of Q4 2023.

  • Macroview Investment Management reported no remaining Editas Medicine position as of Q4 2023 after selling out during the quarter.
  • Macroview Investment Management sold 7 Editas Medicine shares in Q4 2023, an estimated $55.
  • Macroview Investment Management first reported a position in Editas Medicine in Q3 2023 and held it in 1 quarter.
  • Macroview Investment Management's Editas Medicine position peaked at $55 in Q3 2023.
  • 225 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2023.

Based on Macroview Investment Management's 13F filing for Q4 2023, filed 30 Jan 2024.